

GOVERNMENT OF INDIA
MINISTRY OF CHEMICALS AND FERTILIZERS
DEPARTMENT OF PHARMACEUTICALS

LOK SABHA

UNSTARRED QUESTION No. 1515

TO BE ANSWERED ON THE 3rd May, 2016

Removal of Custom Duty Exemption of Life Saving Drugs

1515. SHRI R. DHRUVA NARAYANA:
SHRI BHEEMRAO B. PATIL:
SHRI DALPAT SINGH PARASTE:

Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

- (a) the details of life-saving drugs and bulk drugs used for manufacturing these drugs as well as diagnostic kits removed from customs duty exemption by the Central Board of Excise and Customs (CBEC);
- (b) whether these drugs will now cost 22 per cent more;
- (c) the reasons for removal of these drugs from customs duty exemption and increase in the basic customs duty rate on specified medical devices to 7.5 per cent; and
- (d) the steps being taken by the Government to ensure affordability of these drugs by patients?

ANSWER

MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI HANSRAJ GANGARAM AHIR)

(a): A statement giving life-saving drugs and bulk drugs used for manufacturing these drugs as well as diagnostic kits removed from customs duty exemption by the Central Board of Excise and Customs (CBEC) is given in the attached statement.

(b) & (d): In this regard, National Pharmaceutical Pricing Authority (NPPA) has received various representations from the associations/companies requesting for increase in the prices due to withdrawal of customs duty.

NPPA vide its letter dated 28.3.2016 addressed to associations/companies advised them to absorb the increase in the cost, if any, as DPCO, 2013 does not have any specific provision in this regard.

(c): These drugs and medical devices are being indigenously manufactured. It was represented by the domestic industry that continuation of the exemption/ concession of customs/ excise duty is adversely affecting domestic manufacturers. Therefore, exemption/ concessions were withdrawn in line with the Government of India's 'Make in India' Policy.

xxxxxx

STATEMENT REFERRED TO IN PART (a) OF LOK SABHA UNSTARRED QUESTION NO. 1515 REGARDING REMOVAL OF CUSTOM DUTY EXEMPTION OF LIFE SAVING DRUGS TO BE ANSWERED ON 03.05.2016.

Sl. No.	Description of drugs	Sl. No.	Description of drugs
1.	Allopurinol	38.	Infliximab
2.	Amiodarone	39.	Interlukin-3
3.	Amifostine	40.	Didanosine
4.	Atracurium besylate	41.	Indinavir
5.	Carbidopa with Levodopa	42.	Nelfinavir
6.	Cefoperazone	43.	Stavudine
7.	Ceftizoxime	44.	Abacavir sulphate
8.	Cefpirome	45.	Lopinavir
9.	Dacarbazine	46.	Tenofovir Disoproxil
10.	Desmopressin	47.	Cisplatin
11.	Dobutamine	48.	Dinazole
12.	Disodium Pamidronate	49.	Doxorubicin
13.	Gemcitabine	50.	Etoposide
14.	Ifosfamide	51.	Flutamide
15.	Interferon alpha-2b/interferon alpha NL(LNS)	52.	Flutamide
16.	Ketamine	53.	Ondansetran
17.	Levodopa (L-Dopa)	54.	Paclitaxel
18.	Lamivudine	55.	Tamoxifen citrate
19.	Letrozole	56.	Exemestane
20.	Leuprolide Acetate	57.	Recombinant Human Interferron beta I-a
21.	Mercaptopurine	58.	Rasburicase
22.	Methyl Prednisolone	59.	Posaconazole

23.	Mitomycin	60.	Abciximab
24.	Netilmicin	61.	Anti-Rabies Normal Human immunoglobulin
25.	Naloxone	62.	Anti-D Immunoglobulin
26.	Nitroglycerine	63.	Follicle Stimulating Hormone (FSH)
27.	Micronised Progesterone or Injection	64.	Filgrastim / Molgramostim (G-CSF/GM-CSF)
28.	Pilocarpine	65.	Imatinib Mesilate
29.	Podophyllotoxin	66.	Irinotecan
30.	Piperacillin	67.	Nalorphine
31.	Pralidoxime	68.	Procarbazine
32.	Prazosin	69.	Ritonavir
33.	Streptokinase and Streptodase preparations	70.	Rivastigmine
34.	Tissue Plasminogen Activator	71.	Rituximab
35.	Recombinant human Erythropoietin	72.	Saquinavir
36.	Lopinavir plus Ritonavir (co-formulation of Lopinavir and Ritonavir)	73.	Trastuzumab
37.	Capecitabine		

xxxxxx